ABSTRACT
INTRODUCTION Depressive symptoms are associated with higher risk of dementia but how they impact cognition in diverse populations is unclear.
METHODS Asian, Black, LatinX, or White participants (n=2,227) in the Kaiser Healthy Aging and Diverse Life Experiences (age 65+) and the Study of Healthy Aging in African Americans (age 50+) underwent up to three waves of cognitive assessments over four years. Multilevel models stratified by race/ethnicity were used to examine whether depressive symptoms were associated with cognition or cognitive decline and whether associations differed by race/ethnicity.
RESULTS Higher depressive symptoms were associated with lower baseline verbal episodic memory scores (−0.06, 95%CI:-0.12,-0.01; −0.15, 95%CI:-0.25,-0.04), and faster decline annually in semantic memory (−0.04, 95%CI:-0.07,-0.01; −0.10, 95%CI:-0.15,-0.05) for Black and LatinX participants. Depressive symptoms were associated with lower baseline but not decline in executive function.
DISCUSSION Depressive symptoms were associated with worse cognitive domains, with some evidence of heterogeneity across racial/ethnic groups.
Highlights
We examined whether baseline depressive symptoms were differentially associated with domain-specific cognition or cognitive decline by race/ethnicity.
Depressive symptoms were associated with worse cognitive scores for all racial/ethnic groups across different domains examined.
Higher depressive symptoms were associated with faster cognitive decline for semantic memory for Black and LatinX participants.
The results suggest a particularly harmful association between depressive symptoms and cognition in certain racial/ethnic groups.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study is supported by the National Institute on Aging (NIA) R01AG052132, RF1AG050782. MPJ is supported by 4R00AG066949-03.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human subjects review committees of Kaiser Permanente Northern California and the University of California Davis waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data used in the present study can be accessed via a data use request at https://sites.google.com/g.ucla.edu/khandle-study-site/home.
